focusIR May 2024 Investor Webinar: Blue Whale, Kavango, Taseko Mines & CQS Natural Resources. Catch up with the webinar here.
This paper is better as it is about CAR T-cell phase 1 trials.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9400039/
@stu
Almost all CAR T-cell treatments cause Cytokine Release Syndrome (CRS), perhaps all. Naturally, the grade of CRS is important (1-4). Five to eight years ago, grade 3-4 were unacceptable. Nowadays, grade 3 is tolerable and sometimes even grade 4 can be managed, though it is considered to be life-threatening.
My understanding is that phase 1 is a dose escalation clinical study with safety as primary readout. This means that the researchers will start with the lowest dose of cells. This will allow them to avoid life-threatening situations. This also means that it is highly unlikely that the first patient will cause the termination of the study.
Whingeing, squabbling, attributing blame, and the perpetual creation of conspiracy theories continue endlessly here.
I wish I were in the business of raising money for any company! I wish someone had offered to buy my company out! I wish I had a company! You folks really need to buy DJT shares. If you buy those, then set up accounts on their platform, and voilà - it is profitable! Millions of messages with no meaning, just boring drivel.
And how clever and experienced you are! Someone once said: ‘Those who can, do; those who can’t, teach.’ (Not to offend real teachers.)
“I hope I meet Vlad one day and have a good laugh with him about all this nonsense. Oh, and why are you attacking PR? What has he done to you? What do you know about that guy - a bunch of lowlifes…”
Another Stue the trader/broker!
You have to buy DJT shares together with a bunch of other characters here.
I have about 2.8M shares. It is painful to see their value down 25% on average. My wish is to see less whining and preaching here. None of you (including myself) participate in the day to day life and work of the company. This means that we know only what is in RNSs and interviews given by Vlad. These should be considered as “facts”. The rest is nonsense. When I look at the record, I see a company that is steadily developing and growing against all odds. This is due to the hard work of the hemo’s team including its board and its CEO.
I have looked at REDX record. The company was bashed constantly, its value was just 60M or so and all that was with multiple products in the clinic and a bunch of high profile collaborations. No wonder REDX decided to delist.
I would suggest that you all stop bickering, whining and blaming everyone and everything but rather give the company, its board, CEO, scientists etc. support and encouragement it deserves.
@Saint
You chose the right name. JHFH is totally delusional talking right and left conflating his imagination with reality, talking to me as if I am Vlad or someone else. Crazy fella !
It is too much for me to read. All these conspiracy theories …
I think you invested in a wrong company/wrong sector. It seems to me you have to move to PR and early childhood education.
@justhereforhemo
I looked up the history of RNSs. Hemo issues updates more often than most companies of their size. In reality, they should not be required to issue updates more often than one a quarter. That would be normal for a biotech company.
As for selling assets or fundraising, it is all just a speculation. I would not venture in there myself as I have no clue what is/was available and will happen in the future. Someone once said that the buyer will define when the time to buy is right.
@Charles175
Yes, eventually the company will have to create an account on clinicaltrials.gov for their study. I am not sure if it is obligatory.
@hemotruth
I have not seen biotech companies announcing a start date of their clinical trials in advance . Typically, such companies announce first patient treated or something along these lines. The reason for this is that it is impossible to predict when an actual patient(s) are going to be treated. Formally, hemo has already initiated its clinical study.
@mrindia
What type of trial logistics are you expecting from the company? I do not think they are even allowed to release such things. Also, to tell everyone dates would provoke heavy trading in anticipation of the specific date. What if the date moves by a few weeks up or down? Would you be whining about your shares bought or sold tailored to the date announced? I suggest you either shut up or sell and go away. The reason you are here is either you are stupid buying shares at a wrong moment or have no guts to start your own business to be your own master rather than bashing Vlad or whoever else is in charge. Grow up and take responsibility for your own actions.
Legion Biotechnology has 3 products in phase 3, 3 products in phase 2 and 7 products in phase 1 clinical trials.
Legend received $100M for DLL3 targeting set of therapies including autologous CAR-T after proving to everyone that they can deliver.
https://legendbiotech.com/research-development/pipeline/
Do not twist and confuse people.
@stu
The FDA cannot express any opinion on allogeneic CAR-T as none of them have ever been approved and the number of patients treated is in dozens rather than tens of thousands as in the case of autologous CAR-T. You should stop confusing people who are not experts in the field.
Vlad and directors are not buying most likely because it is prohibited for insiders to buy when a material event is so close.
My understanding is that hemo informed the market about Prevail’s investment before the conference and Vlad’s exchange with someone from Prevail.
At the same time, are you trying to suggest that the company has to constantly talk to the market informing everyone about its activities of fundraising and every step of its R&D efforts? I think that would be stupid on hemo’s part. I watched the video and there is nothing there that shows any definitive data. All it says we are trying and that is our idea.
As far as I understand nothing had been leaked. The video you mentioned is a video made by a conference organizers and was out out on YouTube together with all other videos of presentations at that conference. I watched it several times and cannot see anything that had not been announced in different company RNSs or reports. If you do not like the CEO, vote him out.
@stu I would like you to explain why the IND clearance is not de-risked.
Fantastic! Keep voting. Democracy is the best known to us system.
@one2one you are confusing everyone again. This vaccine is for AML patients that are brought into complete remission. Someone, like hemo, has to put the patients into such remission first.
Vote him out, india, find a respectable leader, stop penny counting, raise 200M-300M and full steam ahead. It your company, do it.